Global Encephalitis Treatment Market to grow with a CAGR of 4.80%
Increasing healthcare infrastructure and a supportive regulatory
environment are the major drivers for the Global Encephalitis Treatment Market.
According to TechSci Research report, “Global Encephalitis Treatment Market
Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Encephalitis Treatment
Market has valued at USD 18.60 billion in 2022 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 4.80% through 2028. This
can be due to collaborations and partnerships among leading companies with a
diverse approach to merge the expertise of individual companies and to
strengthen their position in the market.
Patient-centered care plays a significant role in driving the demand for
the Global Encephalitis Treatment Market. Patient-centered care emphasizes
tailoring treatment plans to the specific needs, preferences, and goals of each
encephalitis patient. This approach recognizes that the presentation and
progression of encephalitis can vary widely between individuals. As a result,
healthcare providers are motivated to offer a range of treatment options and
interventions to address the unique circumstances of each patient. When
patients actively participate in their treatment decisions and have their
preferences considered, they are more likely to adhere to prescribed therapies
and recommendations. This can lead to better treatment outcomes and a reduced
need for additional interventions or hospitalizations. Patient-centered care
fosters open and effective communication between patients, caregivers, and
healthcare providers. This exchange of information is crucial in understanding
the patient's condition, addressing concerns, and making informed treatment
decisions. In a patient-centered approach, patients are encouraged to actively
participate in decisions about their treatment and care plans. This shared
decision-making process empowers patients to have a say in their treatment,
leading to higher patient satisfaction and engagement. Patient-centered care
recognizes the importance of not only treating the medical aspects of
encephalitis but also addressing the broader impact on a patient's quality of
life. This may involve incorporating rehabilitation services, psychological
support, and social services into the care plan.
Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on " Global Encephalitis Treatment Market.”
Encephalitis is an infrequent, yet
severe condition characterized by inflammation of the brain, typically
triggered by factors such as viral or bacterial infections, medication
reactions, or immune system dysfunctions. Timely medical attention is crucial
when encephalitis occurs. Physical manifestations encompass symptoms such as
fever, headaches, and neck discomfort. Additionally, encephalitis can impact
cognitive functions, resulting in confusion and behavioral alterations. In
certain instances, cognitive symptoms persist long after the resolution of
physical manifestations.
In August 2021, Pfizer Inc. has received approval
from the U.S. Food and Drug Administration (FDA) for TICOVAC, a vaccine
designed to actively immunize individuals aged 1 year and older against
tick-borne encephalitis (TBE). This approval marks TICOVAC as the sole FDA-sanctioned
vaccine for safeguarding both adults and children in the United States from the
TBE virus, especially when they are residing in or visiting TBE endemic
regions. With this FDA green light, the U.S. Centres for Disease Control and
Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) is
anticipated to deliberate on recommendations concerning the safe and
appropriate utilization of TICOVAC. TBE, a viral
infection affecting the brain and spinal cord, can be contracted by humans
through the bite of ticks carrying the virus. While TBE is not naturally
occurring in the United States, it has been reported in over 35 countries
spanning Europe and Asia. Presently, the European Centre for Disease Prevention
and Control (ECDC) advises TBE vaccination for individuals residing in or
planning to travel to areas with TBE risk.
Antibiotic resistance is a
challenge in the Global Encephalitis Treatment Market, especially when
encephalitis is caused by bacterial infections. Antibiotic resistance occurs
when bacteria develop the ability to withstand the effects of antibiotics,
rendering these drugs less effective or completely ineffective. In cases where
bacterial encephalitis is suspected or confirmed, the presence of
antibiotic-resistant strains can limit the choice of antibiotics available for
treatment. Identifying antibiotic-resistant bacteria in encephalitis cases may
take time, as specialized laboratory tests are often required. Delayed
diagnosis and initiation of appropriate treatment can lead to more severe
illness and poorer outcomes for patients. The emergence of antibiotic-resistant
strains can result in prolonged hospital stays, increased diagnostic testing,
and the need for more expensive, broad-spectrum antibiotics. This, in turn,
drives up healthcare costs for both patients and healthcare systems. Antibiotic-resistant
bacterial infections, if left untreated or inadequately treated, can lead to
higher mortality rates. Encephalitis caused by antibiotic-resistant bacteria
poses a greater risk to patient survival. Antibiotic resistance is a global
health concern, as resistant bacteria can spread across borders and continents.
This has implications for encephalitis treatment in various regions, as
healthcare providers must be prepared to address antibiotic resistance
effectively.
Global Encephalitis Treatment Market is
segmented based on Type, Treatment, Symptoms, End-User, and by region.
Based on Treatment, Global Encephalitis Treatment Market
is segmented into Antiviral Agents, Steroid Injection, Antibiotics,
Immunoglobulin Therapy, Plasmapheresis, Others. Immunoglobulin therapy,
also known as immunoglobulin replacement therapy or Ig therapy, is a medical
treatment that involves the administration of immunoglobulins (antibodies) to
individuals who have deficiencies in their immune system or certain autoimmune
disorders. Immunoglobulins are proteins produced by plasma cells in the blood
and are a vital component of the immune system. They play a crucial role in
fighting off infections and maintaining immune function. It is prescribed to
individuals with primary immunodeficiency disorders, which are genetic
conditions characterized by a lack of normal antibody production. These
individuals are more susceptible to infections because their immune systems are
unable to produce sufficient antibodies to fight off pathogens. In some
autoimmune disorders, the body's immune system mistakenly attacks its tissues
or organs. Immunoglobulin therapy can help modulate the immune response and
reduce autoantibody levels in certain autoimmune diseases.
Based on Region, North
America dominated the Global Encephalitis
Treatment Market. Governments and private sectors in North America
invest significantly in healthcare and medical research. This investment
supports the development of novel therapies and ensures access to the latest
medical advancements. In many North American countries, healthcare coverage is
widespread, making it easier for individuals to seek medical care for
encephalitis and related conditions. This reduces financial barriers to
treatment. North America often serves as a primary location for clinical trials
of new medications and therapies. This draws both patients and researchers to
the region, contributing to advancements in encephalitis treatment. There is a
relatively high level of awareness about encephalitis in North America, leading
to early recognition of symptoms and prompt medical intervention. Public health
campaigns and educational initiatives also play a role in increasing awareness.
North American healthcare institutions collaborate with international
organizations and researchers to better understand and combat encephalitis on a
global scale.
The Asia-pacific region
witnesses the fastest growth in the Global Encephalitis Treatment Market. The Asia-Pacific region is home
to a significant portion of the global population, and encephalitis can be
caused by a variety of viruses and other pathogens that are prevalent in the
region. This high population density and diverse microbial landscape contribute
to a relatively high disease burden, driving the demand for encephalitis
treatment. Many countries in the Asia-Pacific region experience outbreaks of
viral encephalitis caused by pathogens like Japanese encephalitis virus, dengue
virus, and other arboviruses. The need for both treatment and prevention
(through vaccination) drives market growth. In some parts of the Asia-Pacific
region, access to vaccines for preventable causes of encephalitis may be
limited. This increases the importance of effective treatment options for
individuals who contract the disease. Many countries in the Asia-Pacific region
are experiencing rapid economic growth, leading to increased investments in
healthcare infrastructure. Improved healthcare access, including diagnostic
facilities and specialized treatment centers, contributes to the demand for
encephalitis treatment.
Some of the major companies operating in the Global Encephalitis Treatment Market include:
- Allergan inc.
- Merck & Co., Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Basilea Pharmaceutica Ltd.
- Abbott Laboratories Ltd.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Bayer AG
- Sun Pharmaceutical
Industries Ltd.
Download Free Sample Report
Customers can also request 10% free customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for Encephalitis Treatment.
The growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global Encephalitis
Treatment Market in the forecast period," said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based Global management consulting
firm.
Encephalitis
Treatment Market – Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028, Segmented By Type (Primary Encephalitis, Secondary Encephalitis), By
Treatment (Antiviral Agents, Steroid Injection, Antibiotics, Immunoglobulin
Therapy, Plasmapheresis, Others), By Symptoms (Fever, Drowsiness, Headaches, Personality
Changes, Irritability, Confusion, Weakness, Seizures, Others), by End-User (Clinic,
Hospital, Others), by region, and Competition evaluated the future growth potential of
Global Encephalitis Treatment Market and provides statistics & information
on market size, structure, and future market growth. The report intends to
provide innovative market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in Global
Encephalitis Treatment Market.
Contact
TechSci
Research LLC
420
Lexington Avenue,
Suite 300,
New York,
United
States- 10170
M:
+13322586602
Email: [email protected]
Website: https://www.techsciresearch.com